Literature DB >> 16735718

Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: is there a preferred regimen?

Lawrence H Einhorn, Richard S Foster.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735718     DOI: 10.1200/JCO.2006.05.6184

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Exposure to bleomycin, etoposide, and cis-platinum alters rat sperm chromatin integrity and sperm head protein profile.

Authors:  Jennifer Maselli; Barbara F Hales; Peter Chan; Bernard Robaire
Journal:  Biol Reprod       Date:  2012-05-31       Impact factor: 4.285

2.  Patterns of platinum drug use in an acute care setting: a retrospective study.

Authors:  Evangeline Armstrong-Gordon; Danijela Gnjidic; Andrew J McLachlan; Bayan Hosseini; Andrew Grant; Philip J Beale; Nial J Wheate
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-22       Impact factor: 4.553

3.  Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies.

Authors:  Gautam Jayram; Russell Z Szmulewitz; Scott E Eggener
Journal:  Indian J Urol       Date:  2010 Jan-Mar

4.  The Effects of Chemotherapeutic Agents, Bleomycin, Etoposide, and Cisplatin, on Chromatin Remodeling in Male Rat Germ Cells.

Authors:  Negar Bagheri-Sereshki; Barbara F Hales; Bernard Robaire
Journal:  Biol Reprod       Date:  2016-02-24       Impact factor: 4.285

5.  Effect of Zinc on Spermatogenesis and Sperm Chromatin Condensation in Bleomycin, Etoposide, Cisplatin Treated Rats.

Authors:  Shahnaz Razavi; Farnaz Khadivi; Fatemeh Hashemi; Abbas Bakhtiari
Journal:  Cell J       Date:  2018-08-01       Impact factor: 2.479

6.  "Not all that glitters is gold": insights from the Far East and how to solve a conundrum.

Authors:  Nicholas G Gottardo; Ute Bartels
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.